Post-marketing Experiences with Belimumab in the Treatment of SLE Patients

作者：Askanase Anca D^*; Yazdany Jinoos; Molta Charles T

来源：Rheumatic Disease Clinics of North America, 2014, 40(3): 507-+.

DOI：10.1016/j.rdc.2014.04.007

• SLE
• Lupus
• Belimumab
• Observational studies

Belimumab (Benlysta) is a human recombinant monoclonal antibody that targets and inhibits soluble B-lymphocyte stimulator, also known as B-cell activating factor, a proliferation and survival factor for B cells. The published clinical trials data showed that in patients with active systemic lupus erythematosus (SLE), belimumab effectively reduced peripheral B-cell levels and improved disease activity. This article reviews the belimumab clinical trials and the post-marketing experience with belimumab in the treatment of those lupus patients with persistent active disease despite current standard of care (SOC) therapy.

• 出版日期2014-8